Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
House dust mite allergen extracts (specifically the STG320 formulation) are a sublingual immunotherapy (SLIT) treatment developed by Stallergenes Greer. The product contains standardized extracts from the two most common house dust mite species, *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. It is designed to treat house dust mite-associated allergic rhinitis and allergic asthma by inducing immunological tolerance. The mechanism involves the sublingual administration of allergens, which are taken up by oral mucosal dendritic cells and presented to T-cells, leading to a shift from a Th2-mediated allergic response to a Th1 and regulatory T-cell (Treg) response. This process results in the production of blocking antibodies (IgG4) and a reduction in allergen-specific IgE, ultimately decreasing the inflammatory response upon subsequent exposure to dust mites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on house dust mite allergen extracts.